Molecular Mechanism of Ginseng-Schisandrae Herb Pair in Improving Neurodegenerative Disease on a Network Pharmacology and Molecular Docking

被引:0
|
作者
Ding, Zemin [1 ]
Hong, Xia [2 ]
Li, Xiaohui [3 ]
Wang, Yueyue [2 ]
机构
[1] Chengde Med Univ, Inst Basic Med, Chengde 067000, Hebei, Peoples R China
[2] Chengde Med Univ, Hebei Key Lab Study & Exploitat Chinese Med, Chengde 067000, Hebei, Peoples R China
[3] Henan Univ CM, Affiliated Hosp 1, Dept Cardiovasc, Zhengzhou 450099, Henan, Peoples R China
关键词
Panax Ginseng; NDD; medicine; network pharmacology; molecular docking; PANAX-GINSENG; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; CELL-DEATH; CHINENSIS; IDENTIFICATION; SCHISANTHERIN; BIOMEDICINE; PREDICTION; CULTURES;
D O I
10.23812/j.biol.regul.homeost.agents.20233703.142
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: This study aims to explore the active components of Panax Ginseng (PG)-Schisandrae Chinensis Fructus (SC) and reveal the mechanism of improving neurodegenerative diseases (NDD) based on network pharmacology and molecular docking. Methods: Detailed information about the PG-SC herbal pair was obtained from traditional Chinese medicine systems pharmacology (TCMSP) and screened using OB (oral bioavailability) >= 30% and DL (drug-likeness) >= 0.18 as criteria. Genes were collected using OMIM, Genecards, and PharmGKB (Pharmacogenetics and Pharmacogenomics Knowledge Base) methods. The string database was utilized to obtain protein-protein interaction (PPI) data. The core targets were entered into the "Data Source" of the eFP (electronic Fluorescent Pictograph) browser (http://bar.utoronto.ca/efp_human/) for organ localization and created a target-organ localization map. We constructed and analyzed the network using Cytoscape 3.9.1 (National Institute of General Medical Sciences, Bethesda, MD, USA). Encyclopedia of genomes (KEGG) pathway-enriched targets were used for analysis. After identifying the core network, a protein-protein interaction (PPI) network of PG-SC targets was constructed. Autodock Vina and PyMOL software were used to validate the results for its active ingredients and key targets. Results: There were 14 active ingredients in Ginseng and 8 in Schisandra, with 8320 corresponding protein targets and 80 common targets with neurodegenerative diseases (NDD), of which 21 highly abundant targets were highly expressed in the brain. Six core targets were identified, including AKT1 (RAC-alpha serine/threonine-protein kinase), CASP3 (Caspase 3), MAPK8 (Mitogen-Activated Protein Kinase 8), 1L1B (Interleukin 1 Beta), JUN (Jun Proto-Oncogene, AP-1 Transcription Factor Subunit), and PTGS2 (Prostaglandin-Endoperoxide Synthase 2). The 142 KEGG signaling pathways were enriched, including the pathways of neurodegeneration-multiple diseases and neuroactive ligand-receptor interaction. Molecular docking confirmed that the core targets (AKT1, CASP3, MAPK8, 1L1B, JUN, PTGS2) could bind to the active compounds (Kaempferol, Beta_sitosterol, Conclusions: Based on network pharmacology and molecular docking, the PG-SC herbal pair could act on NDD through neuronal programmed cell death targets and related signaling pathways. Our findings provide the basis for further research using herbs to treat NDD and develop anti-NDD drugs.
引用
收藏
页码:1427 / 1441
页数:15
相关论文
共 50 条
  • [41] Molecular mechanism of vitiligo treatment by bailing tablet based on network pharmacology and molecular docking
    Li, Jinming
    Yang, Meng
    Song, Yeqiang
    MEDICINE, 2022, 101 (26) : E29661
  • [42] To explore the Radix Paeoniae Rubra-Flos Carthami herb pair's potential mechanism in the treatment of ischemic stroke by network pharmacology and molecular docking technology
    Chen, Xingyu
    Wang, Yue
    Ma, Ying
    Wang, Ruonan
    Zhao, Dexi
    MEDICINE, 2021, 100 (49)
  • [43] Possible molecular exploration of herbal pair Haizao-Kunbu in the treatment of Graves' disease by network pharmacology, molecular docking, and molecular dynamic analysis
    Yang, Mengfei
    Lai, Yiwen
    Gan, Di
    Liu, Qingyang
    Wang, Yingna
    He, Xinyong
    An, Yi
    Gao, Tianshu
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [44] The molecular mechanism of "Dahuang-Shengjiang-Banxia decoction" in the treatment of diabetic kidney disease was verified based on network pharmacology and molecular docking
    Xu, Duojie
    Yuan, Ling
    Che, Mengying
    Liu, Wenjing
    Li, Xiangyang
    Yang, Yifan
    Wang, Kaili
    Nan, Yi
    HELIYON, 2024, 10 (02)
  • [45] Exploring the Mechanism of Hepatotoxicity Induced by Dictamnus dasycarpus Based on Network Pharmacology, Molecular Docking and Experimental Pharmacology
    Gao, Peng
    Chang, Kun
    Yuan, Shuo
    Wang, Yanhang
    Zeng, Kewu
    Jiang, Yong
    Tu, Pengfei
    Lu, Yingyuan
    Guo, Xiaoyu
    MOLECULES, 2023, 28 (13):
  • [46] Prediction of the Potential Mechanism of Triptolide in Improving Diabetic Nephropathy by Utilizing A Network Pharmacology and Molecular Docking Approach
    An, Xiaofei
    Fan, Decai
    Yin, Zi
    Zhang, Junhan
    Zhou, Yuexin
    Tian, Ruina
    Yan, Ming
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2022, 27 (03):
  • [47] Network pharmacology and molecular docking technology for exploring the effect and mechanism of Radix Bupleuri and Radix Paeoniae Alba herb-pair on anti-hepatitis: A review
    Huang, Long
    Yu, Qingsheng
    Peng, Hui
    Zhen, Zhou
    MEDICINE, 2023, 102 (48) : E35443
  • [48] The network pharmacology study and molecular docking to investigate the potential mechanism of Acoritataninowii Rhizoma against Alzheimer's Disease
    Zhi-Kun Qiu
    Bai-Xian Zhou
    Jiali Pang
    Wei-qiang Zeng
    Han-biao Wu
    Fan Yang
    Metabolic Brain Disease, 2023, 38 : 1937 - 1962
  • [49] Network Pharmacology Integrated with Molecular Docking Elucidates the Mechanism of Wuwei Yuganzi San for the Treatment of Coronary Heart Disease
    Zhang, Qunhui
    Guo, Yang
    Zhang, Dejun
    NATURAL PRODUCT COMMUNICATIONS, 2022, 17 (04)
  • [50] Network Pharmacology and Molecular Docking to Unveil the Mechanism of Shudihuang against Amyotrophic Lateral Sclerosis
    Li, Xiaojing
    Tian, Yueqin
    Wu, Haidong
    Wang, Tong
    CURRENT PHARMACEUTICAL DESIGN, 2023, 29 (19) : 1535 - 1545